"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04317092","Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)","TOCIVID-19","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab Injection","One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples","All","Child, Adult, Older Adult","Phase 2","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOCIVID-19|2020-001110-38","March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",,"April 7, 2020","Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy|ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy|Azienda Ospedaliero-Universitaria di Modena, Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy|National Cancer Institute, Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy|Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy|ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy|A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy|Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy",,"https://ClinicalTrials.gov/show/NCT04317092"
2,"NCT04345445","Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression",,"Not yet recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Drug: Methylprednisolone","The proportion of patients requiring mechanical ventilation|Mean days of ventilation|The proportion of patients requiring ICU admission|Overall 28-day survival|Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline|Duration of hospital and ICU stay","University of Malaya","All","18 Years and older   (Adult, Older Adult)","Phase 3","310","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TVCS-COVID19","April 15, 2020","October 31, 2020","October 31, 2020","April 14, 2020",,"April 14, 2020","University Malaya Medical Centre, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT04345445"
3,"NCT04331795","Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis","COVIDOSE","Completed","No Results Available","COVID-19","Drug: Tocilizumab","Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days|Duration of Increased Supplemental Oxygen Requirement from Baseline","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0515","April 4, 2020","June 5, 2020","June 5, 2020","April 2, 2020",,"June 9, 2020","University of Chicago Medicine, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04331795"
4,"NCT04412772","A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS","ARCHITECTS","Recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Drug: Placebo","Clinical status (on a 7-point ordinal scale) at day 28|Clinical improvement|Mechanical Ventilation|Oxygenation","Queen's Medical Centre","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RA-2020-019","June 1, 2020","December 31, 2021","December 31, 2021","June 2, 2020",,"June 2, 2020","Queen's Medical Center, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT04412772"
5,"NCT04377750","The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation",,"Recruiting","No Results Available","Covid19 Pneumonia","Drug: Tocilizumab","Survival","Hadassah Medical Organization|Sheba Medical Center|Wolfson Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0224-20-HMO-CTIL","April 8, 2020","April 29, 2020","May 8, 2021","May 6, 2020",,"May 6, 2020","Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel|Barzilai Medical Center, Ashkelon, Israel|Wolfson Medical Center, H̱olon, Israel|Sheba Medical Center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT04377750"
6,"NCT04361032","Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia","TRONCHER","Not yet recruiting","No Results Available","COVID19|Intensive Care Unit","Drug: Tocilizumab Injection|Drug: Deferoxamine","the mortality rate","Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Datametrix","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECC2020-06","May 4, 2020","September 4, 2020","October 4, 2020","April 24, 2020",,"May 6, 2020","Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Ariana, Tunisia",,"https://ClinicalTrials.gov/show/NCT04361032"
7,"NCT04359667","Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab","UHID-COVID19","Not yet recruiting","No Results Available","COVID-19|Severe Pneumonia","Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]","serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab","University Hospital for Infectious Diseases, Croatia","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UHID-04","June 16, 2020","April 16, 2021","May 15, 2021","April 24, 2020",,"June 9, 2020","University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia",,"https://ClinicalTrials.gov/show/NCT04359667"
8,"NCT04332094","Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","TOCOVID","Recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin","In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III","All","18 Years and older   (Adult, Older Adult)","Phase 2","276","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIBSP-COV-2020-23","April 2, 2020","September 2020","October 2020","April 2, 2020",,"April 7, 2020","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04332094"
9,"NCT04377659","Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection",,"Recruiting","No Results Available","COVID-19","Drug: Tocilizumab","Progression of respiratory failure or death","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-185","May 1, 2020","May 1, 2021","May 1, 2021","May 6, 2020",,"May 29, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04377659"
10,"NCT04424056","An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease","INFLAMMACOV","Not yet recruiting","No Results Available","Covid19","Drug: Anakinra +/- Ruxolitinib (stages 2b/3)|Drug: Anakinra and Ruxolitinib (Advanced stage 3)|Drug: Tocilizumab +/- ruxolitinib (stages 2b/3)|Drug: Tocilizumab and Ruxolitinib (Advanced stage 3)|Other: Standard of care","Ventilation free days at D28","Assistance Publique Hopitaux De Marseille","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","216","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-23","September 1, 2020","September 30, 2022","November 1, 2022","June 9, 2020",,"June 9, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT04424056"
11,"NCT04346355","Efficacy of Early Administration of Tocilizumab in COVID-19 Patients",,"Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab","Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count","Azienda Unità Sanitaria Locale Reggio Emilia","All","18 Years and older   (Adult, Older Adult)","Phase 2","398","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RCT-TCZ-COVID-19|2020-001386-37","March 31, 2020","May 30, 2020","May 30, 2020","April 15, 2020",,"June 9, 2020","Ospedale di Guastalla, Guastalla, RE, Italy|Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|ASST Cremona, Cremona, Italy|Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Ospedale Evangelico Internazionale di Genova, Genova, Italy|Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy|Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|IRCCS Istituto Auxologico Italiano Milano, Milano, Italy|Azienda Ospedaliero-Universitaria ""Maggiore della Carità"" di Novara, Novara, Italy|Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy|Azienda Ospedaliero-Universitaria Parma, Parma, Italy|Azienda Unità Sanitaria Locale di Piacenza, Piacenza, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|AO Ordine Mauriziano di Torino, Torino, Italy|ASST Bergamo Ovest -Treviglio, Treviglio, Italy|AULSS 2 Marca Trevigiana, Treviso, Italy|AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy|AULSS 3 Serenissima Ospedale ""Dell'Angelo"", Venezia, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|IRCCS Sacro Cuore Don Calabria, Verona, Italy",,"https://ClinicalTrials.gov/show/NCT04346355"
12,"NCT04335071","Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","CORON-ACT","Recruiting","No Results Available","SARS-CoV-2 Infection","Drug: Tocilizumab (TCZ)|Drug: Placebo","Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days)","University Hospital Inselspital, Berne|Roche Pharma AG","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-00691|2020DR2044","April 26, 2020","October 2020","October 2020","April 6, 2020",,"April 28, 2020","University Hospital Bern (Inselspital), Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Ospedale Regionale di Lugano (EOC), Viganello, Switzerland|University Hospital Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04335071"
13,"NCT04412291","A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",,"Not yet recruiting","No Results Available","Covid-19","Drug: Anakinra Prefilled Syringe|Drug: Tocilizumab Prefilled Syringe|Drug: Standard-of-care treatment","Time to recovery|Mortality|Number of Days on mechanical ventilation|Number of days of supplemental oxygen use|Number of patients requiring initiation of mechanical ventilation|Time to improvement in oxygenation for at least 48 hours|Mean change in the 8-point ordinal scale|Proportion of patients on level e-h on the 8-point ordinal scale at day 15|Time to improvement in one category from admission using the 8-point ordinal scale|Mean change in Sequential organ failure assessment score (SOFA)|Time to resolution of fever for at least 48 hours by clinical severity|Time to change in National Early Warning Score 2 (NEWS2) scoring system|Time to score of <2 maintained for 24 hours in NEWS2 scoring system (National Early Warning Score)|Mean change in NEWS2 scoring system (National Early Warning Score)|Number of days with fever|Number of days of resting respiratory rate >24 breaths/min|Time to saturation ≥94% on room air|Incidence of serious adverse events|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia|Incidence of hypersensitivity reactions|Incidence of infusion reactions|Number of ventilator free days in the first 28 days|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients requiring Extracorporeal membrane oxygenation (ECMO)|Number of patients that have been admitted into an intensive care unit (ICU)|Number of days of hospitalization in survivors|Number of deaths due to any cause","Jon Lampa|Karolinska University Hospital|Karolinska Institutet","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001748-24","June 2020","August 2020","February 2021","June 2, 2020",,"June 4, 2020","Karolinska University Hospital, Huddinge, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04412291"
14,"NCT04403685","Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers","TOCIBRAS","Recruiting","No Results Available","COVID|SARS Pneumonia|Cytokine Release Syndrome","Drug: Tocilizumab","Evaluation of clinical status|All-cause mortality|Inpatient Mortality|Improvement of Sequential Sepsis-related Organ Failure Assessment (SOFA) scale|Ventilator free days|Time until oxygen support independence|Need of mechanical ventilation support|Days to mechanical ventilation support.|Duration of hospitalization|Other infections|Incidence of thromboembolic events|Incidence of adverse events","Beneficência Portuguesa de São Paulo|Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Hospital Alemão Oswaldo Cruz|Brazilian Research In Intensive Care Network|Hospital Moinhos de Vento|Brazilian Clinical Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOCIBRAS","May 8, 2020","July 8, 2020","August 31, 2020","May 27, 2020",,"May 28, 2020","UNIFESP, São Paulo, Sao Paulo, Brazil|HCOR -Hospital do Coracao, Sao Paulo, SP, Brazil|HAOC - Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil|Beneficência Portuguesa de Sao Paulo, Sao Paulo, Brazil|HAOC - Hospital Alemao Oswaldo Cruz - unidade Vergueiro, Sao Paulo, Brazil|HIAE - Hospital Israelita Albert Einstein, Sao Paulo, Brazil|HSL - Hospital Sírio Libanês, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04403685"
15,"NCT04356937","Efficacy of Tocilizumab on Patients With COVID-19",,"Not yet recruiting","No Results Available","SARS-CoV 2","Drug: Tocilizumab|Drug: Placebos","Proportion of patients that require mechanical ventilation|Requirement for inotropes and/or vasopressors|8-level Clinical improvement Scale|Duration of mechanical ventalition|Hospital discharge|Mortality|Duration of ICU stay|Duration of time on supplemental oxygen|The proportion of patients who require renal replacement therapy or have doubling of creatinine","Massachusetts General Hospital|Genentech, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","300","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2020P001159","April 27, 2020","June 30, 2020","August 30, 2020","April 22, 2020",,"April 22, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04356937"
16,"NCT04372186","A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia",,"Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Placebo|Drug: Tocilizumab","Cumulative Proportion of Participants Requiring Mechanical Ventilation by Day 28|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate by Day 28|Time to Hospital Discharge or ""Ready for Discharge"" (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or >/= 2 liters (L) supplemental oxygen)|Percentage of Participants with Adverse Events|Percentage of Participants with any Post-Treatment Bacterial and/or Fungal Infection|Incidence of Post-Treatment Acute Kidney injury (defined by 50% increase of creatinine from baseline)","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","379","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ML42528","May 14, 2020","August 5, 2020","October 5, 2020","May 1, 2020",,"May 29, 2020","Banner - University Medical Center Phoenix; In-Patient Pharmacy, Phoenix, Arizona, United States|Univ of AZ Coll of Med, Tucson, Arizona, United States|Scripps Mercy Hospital, Chula Vista, California, United States|El Centro Regional Medical Center, El Centro, California, United States|eStudySite, La Mesa, California, United States|Riverside University Health System-Medical Center, Moreno Valley, California, United States|Highland Hospital Oakland, Oakland, California, United States|San Leandro Hospital; Inpatient Pharmacy, San Leandro, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Howard University, Washington, District of Columbia, United States|Westchester General Hospital, Miami, Florida, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Uni of Kansas Medical Center, Kansas City, Kansas, United States|Ochsner Clinic, New Orleans, Louisiana, United States|LSU-Shreveport, Shreveport, Louisiana, United States|Holy Cross Germantown Hospital, Germantown, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Optum Health Care, Las Vegas, Nevada, United States|St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|St. Barnabas Hospital, Bronx, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Elmhurst Hospital Center, Elmhurst, New York, United States|Flushing Hospital, Flushing, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Harlem Hospital, New York, New York, United States|Canton-Potsdam Hospital, Potsdam, New York, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Sanford Health System, Sioux Falls, South Dakota, United States|Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04372186"
17,"NCT04320615","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","COVACTA","Active, not recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab (TCZ)|Drug: Placebo","Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WA42380|2020-001154-22","April 3, 2020","August 31, 2020","September 30, 2020","March 25, 2020",,"June 1, 2020","University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Denver Health Medical Center, Denver, Colorado, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Baystate Health System, Springfield, Massachusetts, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States|James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital - HCHD, Houston, Texas, United States|Intermountain Medical Group, Saint George, Utah, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States|Evergreen Health Infectious Disease, Kirkland, Washington, United States|Swedish Hospital Medical Center, Seattle, Washington, United States|Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Clinical Research Institute of Montreal, Montreal, Quebec, Canada|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier et Universitaire de Limoges, Limoges, France|Hôpital de La Croix Rousse, Lyon, France|Hotel Dieu - Nantes, Nantes, France|Hopital de la Pitie Salpetriere, Paris, France|HOPITAL COCHIN university hospital, Paris, France|CHRU de Tours, Pharmacie, Tours, France|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany|Uniklinik Köln, Köln, Germany|LMU Klinikum der Universitat Munchen, Munchen, Germany|Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy|ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy|Amphia Ziekenhuis, Breda, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain|Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|University College Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|St George's Clinical Research Facility, London, United Kingdom|Imperial College London, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Salford Royal Hospital, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04320615"
18,"NCT04363736","A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia","MARIPOSA","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tociliuzumab","Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ|Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ|Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ|Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ|Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ|Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ|Pecentage of Participants with Adverse Events|Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time|Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with any Post-Treatment Infection","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA42481","May 5, 2020","July 3, 2020","August 3, 2020","April 27, 2020",,"June 2, 2020","Mayo Clinic - Arizona, Phoenix, Arizona, United States|Univ of AZ Coll of Med, Tucson, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|LAC + USC Medical Center, Los Angeles, California, United States|USC Keck Medical Center of USC, Los Angeles, California, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|University of Florida; Health Science Center, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|MedPharmics, Metairie, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Renown Institute for Heart & Vascular Health, Reno, Nevada, United States|St Joseph's Regional Medical Center, Wayne, New Jersey, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Houston Methodist Hospital, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04363736"
19,"NCT04377503","Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19",,"Not yet recruiting","No Results Available","Cytokine Release Syndrome|Covid-19","Drug: Tocilizumab 180 MG/ML|Drug: Methylprednisolone Sodium Succinate","Patient clinical status 15 days after randomization|Improving oxygenation|Thorax CT improvement|ICU length of stay|Duration of mechanical ventilation|Incidence of acute kidney (AKI) with necessity of renal replacement therapy","Hospital Sao Domingos","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","covid-19 hsd","May 2020","August 2020","November 2020","May 6, 2020",,"May 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04377503"
20,"NCT04332913","Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia","TOSCA","Recruiting","No Results Available","COVID-19 Pneumonia",,"Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.|Percentage of patients achieving a score <3 on the Brescia-COVID respiratory severity scale (BCRSS) after the last tocilizumab administration.|Percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab.|Duration of hospitalization|Time to the first negative SARS-CoV-2 negative RT-PCR test|Changes from the baseline in the white blood cell count|Changes from the baseline in the lymphocyte populations (cluster of differentiation (CD)3+CD4+, CD3+CD8+, CD19+, Th17)|Changes from the baseline of c-reactive protein (CRP) values|Changes from the baseline of Ferritin values|Changes from the baseline of BNP values|Changes from the baseline of CK-MB values|Changes from the baseline of Troponin values|Changes from the baseline of LDH values|Changes from the baseline of myoglobulin values|Changes in myocardial ischemia signs at the electrocardiographic trace (YES or NO)|Rate of adverse events report during and after tocilizumab|Mortality (number of Partecipants, cause and timing)|Percentage of patients who develop autoimmune diseases","University of L'Aquila","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0064468/20","April 1, 2020","December 31, 2020","March 31, 2021","April 3, 2020",,"April 13, 2020","Ospedale San Salvatore, L'Aquila, Italy",,"https://ClinicalTrials.gov/show/NCT04332913"
21,"NCT04363853","Tocilizumab Treatment in Patients With COVID-19",,"Recruiting","No Results Available","Sars-CoV2","Drug: Tocilizumab","Hematic biometry|Blood chemistry|Blood gas|blood gas|thorax radiography","Instituto Nacional de Cancerologia de Mexico|Roche Pharma AG","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","200","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INF-3343-20-22-1","April 1, 2020","June 1, 2020","August 1, 2020","April 27, 2020",,"April 27, 2020","National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico",,"https://ClinicalTrials.gov/show/NCT04363853"
22,"NCT04409262","A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia","REMDACTA","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo","Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Day 28|Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Clinical Status as Assessed by the Investigator Using a 7-Category Ordinal Scale of Clinical Status on Days 7, 14, and 21|Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline|Ventilator-Free Days from Randomization to Day 28|Proportion of Participants Requiring Initiation of Intensive Care Unit (ICU) Care Post-baseline|Duration of ICU Stay in Days|Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)|Mortality Rate on Days 7, 14, 21, 28, and 60|Time to Recovery, Defined as Time from Randomization to the Time when a Category of 2, Non-ICU Hospital Ward (or ""Ready for Hospital Ward"") not Requiring Supplemental Oxygen, or Better is Observed|Time from Randomization to Hospital Discharge or ""Ready for Discharge"" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or </= 2L Supplemental Oxygen)|Duration of Supplemental Oxygen Use","Hoffmann-La Roche|Gilead Sciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WA42511|2020-002275-34","May 31, 2020","July 31, 2020","July 31, 2020","June 1, 2020",,"June 1, 2020","eStudySite - Chula Vista - PPDS, Chula Vista, California, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States|Boston Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Michael'S Medical Center, Newark, New Jersey, United States|Intermountain LDS Hospital, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04409262"
23,"NCT04335305","Checkpoint Blockade in COVID-19 Pandemic","COPERNICO","Recruiting","No Results Available","COVID-19|Pneumonia, Viral","Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475)","Percentage of patients with normalization of SpO2 ≥96% on room air (measured without any respiratory support for at least 15 minutes|Proportion of patients discharged from the emergency department and classified as low risk|Number of days of patient hospitalization|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test|Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)","MedSIR","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MedOPP376","July 1, 2020","August 30, 2020","August 30, 2020","April 6, 2020",,"June 9, 2020","Hospital Quirónsalud Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Ruber Juan Bravo, Madrid, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Arnau de Vilanova-Lliria, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04335305"
24,"NCT04306705","Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19","TACOS","Recruiting","No Results Available","Covid-19|SARS|Cytokine Storm|Cytokine Release Syndrome|Tocilizumab","Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy","Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Duration of hospitalization|Proportion of Participants With Normalization of Fever Through Day 14|Change from baseline in white blood cell and differential count|Time to first negative in 2019 novel Corona virus RT-PCR test|All-cause mortality|Change from baseline in hsCRP|Change from baseline in cytokines IL-1β, IL-10, sIL-2R, IL-6, IL-8 and TNF-α|Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells","Tongji Hospital|Hubei Xinhua Hospital|Wuhan No.1 Hospital|Wuhan central hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","WHTJCOVID-19","February 20, 2020","May 30, 2020","June 20, 2020","March 13, 2020",,"March 17, 2020","Tongji Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04306705"
25,"NCT04310228","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019",,"Recruiting","No Results Available","COVID-19","Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab","Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time","Peking University First Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020YFC0844100","March 8, 2020","May 2020","May 2020","March 17, 2020",,"April 10, 2020","Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04310228"
26,"NCT04370834","Tocilizumab for Patients With Cancer and COVID-19 Disease",,"Recruiting","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Pneumonia|Pneumonitis|Severe Acute Respiratory Distress Syndrome|Symptomatic COVID-19 Infection Laboratory-Confirmed","Biological: Tocilizumab","Frequency of response|Length of time from level of care to step down level of care|Survival","National Cancer Institute (NCI)","All","2 Years and older   (Child, Adult, Older Adult)","Phase 2","200","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NCI-2020-02987|TRC-10446","May 28, 2020","January 1, 2022","January 1, 2022","May 1, 2020",,"June 9, 2020","National Cancer Institute, Rockville, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04370834"
27,"NCT04339712","Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction","ESCAPE","Recruiting","No Results Available","COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection","Drug: Anakinra|Drug: Tocilizumab","Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function","Hellenic Institute for the Study of Sepsis","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ESCAPE|2020-001039-29","April 2, 2020","April 1, 2022","April 1, 2022","April 9, 2020",,"April 22, 2020","2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece|Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece|Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece|4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece|Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece|Intensive Care Unit, ""Latsio"", Thriasio Elefsis General Hospital, Elefsína, Greece|Intensive Care Unit, ""Koutlimbaneio & Triantafylleio"" Larissa General Hospital, Larissa, Greece|Department of Internal Medicine, Larissa University Hospital, Larissa, Greece|Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece|Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT04339712"
28,"NCT04315480","Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis",,"Active, not recruiting","No Results Available","SARS Pneumonia","Drug: Tocilizumab","arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death","Università Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","38","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOCICOV-1","March 12, 2020","April 9, 2020","May 2020","March 19, 2020",,"April 13, 2020","Università Politecnica delle Marche, Ancona, AN, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04315480"
29,"NCT04333914","Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection","IMMUNONCOVID","Recruiting","No Results Available","SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor","Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab","28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA)","Centre Leon Berard","All","18 Years and older   (Adult, Older Adult)","Phase 2","384","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ET20-076 - IMMUNONCOVID-20|2020-001373-70","April 15, 2020","June 2020","August 2020","April 3, 2020",,"June 9, 2020","Centre Léon Bérard, Lyon, Rhône, France|CHU Clermont Ferrand, Clermont Ferrand, France|Centre Oscar Lambret, Lille, France|AP-HP Hôpital Saint Antoine, Paris, France|AP-HP La Pitié Salpétrière, Paris, France|Hôpital Saint-Joseph, Paris, France|AP-HP Tenon, Paris, France|AP-HP Hôpital Bichat Claude Bernard, Paris, France|GH Diaconesses Croix Saint Simon, Paris, France|Gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT04333914"
30,"NCT04423042","Tocilizumab in Coronavirus-19 Positive Patients",,"Not yet recruiting","No Results Available","Covid19|COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2|Coronavirus|Inflammation","Biological: Tocilizumab","All-cause mortality|Ordinal Scale for evaluating subject clinical status at days 3, 8, 15, 30, 60 post treatment.","University of Calgary|Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REB20-0713","June 2020","June 2021","June 2021","June 9, 2020",,"June 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04423042"
31,"NCT04361552","Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)",,"Recruiting","No Results Available","Cerebrovascular Accident|Chronic Obstructive Pulmonary Disease|Chronic Renal Failure|Coronary Artery Disease|Diabetes Mellitus|Malignant Neoplasm|SARS Coronavirus 2 Infection","Other: Best Practice|Biological: Tocilizumab","7-day length of invasive mechanical ventilation (MV)|30-day mortality rate|Rate of intensive care (ICU) transfer|Rate of invasive mechanical ventilation|Rate of tracheostomy|Length of ICU stay|Length of hospital stay","Emory University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","180","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000419|NCI-2020-02314|WINSHIP4998-20|P30CA138292","May 30, 2020","May 30, 2022","May 30, 2022","April 24, 2020",,"April 24, 2020","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04361552"
32,"NCT04380519","Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)",,"Recruiting","No Results Available","COVID-19","Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo","Proportion of patients, responded to the study therapy, in each of the treatment groups|Changes of patients' clinical status on a 6 points ordinal scale over time|Mortality rate over the follow-up period|Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.|Proportion of patients received tocilizumab or sarilumab due to COVID-19","R-Pharm International, LLC|Data Management 365 LLC|K-Research, LLC|R-Pharm","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2|Phase 3","372","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CL04041078","April 23, 2020","October 15, 2020","November 15, 2020","May 8, 2020",,"May 8, 2020","Federal State Budget Institution ""National Medical Surgery Center named after N.I. Pirogov"" of Ministry of Health of Russian Federation, Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital № 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation|Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation|Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation|State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation|Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital #40"", Moscow City Healthcare Department, ""Communarca"" Division, Moscow, Russian Federation|АО ""State Company ""Medsi"" based on Clinical Hospital №1"", Moscow, Russian Federation|Saint Petersburg State Budget Institution of Healthcare ""Clinical infectious diseases hospital named after S.P. Botkin"", Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Institution of Healthcare ""City Hospital №40"", Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04380519"
33,"NCT04330638","Treatment of COVID-19 Patients With Anti-interleukin Drugs","COV-AID","Recruiting","No Results Available","COVID-19","Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab","Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre","All","18 Years and older   (Adult, Older Adult)","Phase 3","342","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COV-AID","April 2020","September 2020","December 2020","April 1, 2020",,"April 24, 2020","AZ Sint-Jan Brugge, Brugge, Belgium|University Hospital Saint-Pierre, Brussels, Belgium|Erasmus University Hospital, Brussels, Belgium|University Hospital Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Ziekenhuis Oost-Limurg, Genk, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jessa ZH, Hasselt, Belgium|University Hospital Brussels, Jette, Belgium|CHU Tivoli, La Louvière, Belgium|CHR de la Citadelle, Liège, Belgium|University Hospital Liège, Liège, Belgium|Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium|AZ Delta, Roeselare, Belgium",,"https://ClinicalTrials.gov/show/NCT04330638"
34,"NCT04322773","Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure","TOCIVID","Recruiting","No Results Available","Corona Virus Disease","Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care","Time to independence from supplementary oxygen therapy|Number of deaths|Days out of hospital and alive|Ventilator free days alive and out of hospital|C-reactive protein (CRP) level|Number of participants with serious adverse events","Marius Henriksen|Lars Erik Kristensen|Frederiksberg University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APPI2-CV-2020-01","April 5, 2020","June 1, 2021","June 1, 2021","March 26, 2020",,"April 7, 2020","Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark|Hillerød Hospital, Hillerød, Denmark",,"https://ClinicalTrials.gov/show/NCT04322773"
35,"NCT04386239","Study on the Use of Sarilumab in Patients With COVID-19 Infection",,"Not yet recruiting","No Results Available","COVID19","Drug: Sarilumab Prefilled Syringe","Proportion of patients who show an improvement of the respiratory function|Evaluation of the time to resolution of fever|Evaluation of the viral load on blood and sputum for COVID-19|Evaluation of the plasma concentration of GM-CSF|Evaluation of the plasma concentration of Il-6|Evaluation of the plasma concentration of TNF-α|Evaluation of the rate of progression of White Blood Cell (WBC) fraction","ASST Fatebenefratelli Sacco","All","18 Years to 84 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-SARI-001","May 2020","December 2020","December 2020","May 13, 2020",,"May 13, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT04386239/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04386239"
36,"NCT04381936","Randomised Evaluation of COVID-19 Therapy","RECOVERY","Recruiting","No Results Available","Severe Acute Respiratory Syndrome","Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab","All-cause mortality|Duration of hospital stay|Need for (and duration of) ventilation|Composite endpoint of death or need for mechanical ventilation or ECMO","University of Oxford|UK Research and Innovation|National Institute for Health Research, United Kingdom|Wellcome|Bill and Melinda Gates Foundation|Department for International Development, United Kingdom|Health Data Research UK|Medical Research Council Population Health Research Unit|NIHR Clinical Trials Unit Support Funding","All","Child, Adult, Older Adult","Phase 2|Phase 3","12000","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NDPHRECOVERY|2020-001113-21|ISRCTN50189673","March 19, 2020","December 2020","June 2021","May 11, 2020",,"June 5, 2020","Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04381936"
37,"NCT04331808","CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)","CORIMUNO-TOC","Active, not recruiting","No Results Available","Corona Virus Infection","Drug: Tocilizumab","Survival without needs of ventilator utilization at day 14. Group 1|WHO progression scale <=5 at day 4. Group 1.|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14. Group 2.|WHO progression scale at day 4. Group 2.|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","228","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-1","March 30, 2020","March 31, 2021","December 31, 2021","April 2, 2020",,"April 28, 2020","APHP- Hopital Tenon, Paris, France|APHP - Beaujon, Paris, France|APHP - Bichat, Paris, France|APHP - Hopital Necker, Paris, France|APHP - Pitié Salpêtrière, Paris, France|APHP - Saint Louis, Paris, France|CHU Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT04331808"
38,"NCT04366206","Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est",,"Recruiting","No Results Available","COVID|SARS-CoV 2",,"Composite of death and mechanical ventilation|Need for mechanical ventilation|Death|Acute kidney injury|Acute respiratory distress syndrome|Cardiac arrhythmia and conduction disorder|60-days mortality|60-days mechanical ventilation","Centre Hospitalier Intercommunal Robert Ballanger|Groupe Hospitalier Pitie-Salpetriere","All","Child, Adult, Older Adult",,"143","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GHTRB-2020-01","March 14, 2020","July 31, 2020","July 31, 2020","April 28, 2020",,"April 28, 2020","Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Groupe Hospitalier Pitie Salpetriere, Paris, France",,"https://ClinicalTrials.gov/show/NCT04366206"
39,"NCT04409522","Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients",,"Recruiting","No Results Available","COVID-19","Drug: Melatonin|Drug: The usual treatment","Melatonin|Inflammatory cytokines|C-reactive protein (CRP)|Cough|Oxygen saturation of the blood|ESR|Radiological Treatment Response|Inflammatory route","Mohammad Sadegh Bagheri Baghdasht|Baqiyatallah Medical Sciences University","All","16 Years to 100 Years   (Child, Adult, Older Adult)","Not Applicable","55","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IR.BMSU.REC.1399.039","May 12, 2020","June 5, 2020","September 25, 2020","June 1, 2020",,"June 1, 2020","Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04409522"
40,"NCT04359095","Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment","Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection","Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","76968","May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",,"April 24, 2020","Hospital Universitario de Neiva, Neiva, Huila, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia",,"https://ClinicalTrials.gov/show/NCT04359095"
41,"NCT04347031","A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19",,"Active, not recruiting","No Results Available","Pneumonia, Viral|Respiratory Failure","Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab","1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2","Burnasyan Federal Medical Biophysical Center","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FL-01/20","April 8, 2020","August 1, 2020","August 1, 2020","April 15, 2020",,"May 27, 2020","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04347031"
42,"NCT04365764","Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study",,"Recruiting","No Results Available","Covid-19|ARDS|Pneumonia",,"Composite of death and mechanical ventilation|Death|Mechanical ventilation|World Health Organization score","Groupe Hospitalier Pitie-Salpetriere|Centre Hospitalier Intercommunal Robert Ballanger|Centre Hospitalier Intercommunal Montfermeil-Le Raincy|CMC Ambroise Paré","All","Child, Adult, Older Adult",,"400","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","CIC1421-20-06","March 14, 2020","May 31, 2020","December 31, 2020","April 28, 2020",,"May 20, 2020","Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France",,"https://ClinicalTrials.gov/show/NCT04365764"
43,"NCT04388514","Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure","CORMOR","Recruiting","No Results Available","SARS-CoV-2 Respiratory Failure","Procedure: Medical Ozone procedure","Time of respiratory improvement and earlier weaning from oxygen support|The time of respiratory improvement and earlier weaning from oxygen support|Assessment of the length of hospitalization|Assessment of the length of Intensive Care Unit (ICU) stay|Improvment in chest imaging finding|Improvment in cytokine release syndrome","Azienda Sanitaria-Universitaria Integrata di Udine|Fondazione Toscana Gabriele Monasterio|Policlinico Militare, Roma - Italy|Ospedale San Liberatore di Atri|Ospedale Umberto I di Torino|Università di Siena|Ospedale Civile di Lucca|Ospedale di Siracusa|Azienda Sanitaria Locale di Vercelli","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","CIG: Z7C2CA5837","April 8, 2020","October 8, 2020","October 8, 2020","May 14, 2020",,"May 14, 2020","Dott. Amato De Monte, Udine, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04388514/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04388514"
44,"NCT04380818","Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19",,"Recruiting","No Results Available","Pneumonia, Viral","Radiation: Low-dose radiotherapy|Drug: Hydroxychloroquine Sulfate|Drug: Ritonavir/lopinavir|Drug: Tocilizumab Injection [Actemra]|Drug: Azithromycin|Drug: Corticosteroid|Drug: Low molecular weight heparin|Device: Oxygen supply","Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change of the radiological image|Overall mortality|Measure of pro-inflammatory interleukins|Measure of trasforming growth factor (TGF-b)|Measure of tumor necrosis factor alpha (TNF-a)|Determining overexpression of pro-inflammatory selectin|Determining cell adhesion molecules (CAMs)|Measure of marker of oxidative stress PON-1","Grupo de Investigación Clínica en Oncología Radioterapia|Hospital Universitario Madrid Sanchinarro|Hospital del Mar|Hospital Universitari Sant Joan de Reus","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","106","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IPACOVID","May 8, 2020","May 4, 2021","July 1, 2021","May 8, 2020",,"June 1, 2020","Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04380818"
45,"NCT02735707","Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","REMAP-CAP","Recruiting","No Results Available","Community-acquired Pneumonia, Influenza, COVID-19","Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab","All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome","MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht","All","18 Years and older   (Adult, Older Adult)","Phase 4","7100","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584","April 11, 2016","December 2021","December 2023","April 13, 2016",,"April 16, 2020","St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02735707"
46,"NCT04349410","The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","FMTVDM","Enrolling by invitation","No Results Available","CoVid 19 Positive","Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum","Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status","The Camelot Foundation","All","Child, Adult, Older Adult","Phase 2|Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","FMTVDM2020","April 11, 2020","October 11, 2020","November 11, 2020","April 16, 2020",,"April 17, 2020","FHHI-OI-Camelot; QME, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04349410"
47,"NCT04374539","Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial","REP-COVID","Recruiting","No Results Available","Coronavirus","Biological: Plasma exchange|Drug: Standar medical treatmen","Impact of plasma exchange","Fundacion Clinic per a la Recerca Biomédica","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001722-66","April 29, 2020","May 5, 2021","August 29, 2021","May 5, 2020",,"May 5, 2020","Hospital Clinic i Provincial de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04374539"
48,"NCT04346693","An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19",,"Active, not recruiting","No Results Available","Acute Respiratory Tract Infection|Acute Respiratory Insufficiency|Pneumonia|Septic Shock|Hypoxemia","Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation","The change of viral load in patients with SARS-COVID-19.|The frequency of development of Acute Respiratory Distress Syndrome (ADRS)|Duration of hospitalization|The frequency of early mortality|The frequency of late mortality|Clinical status at the time of completion of participation in the study","Burnasyan Federal Medical Biophysical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAL-05-04-2020","April 8, 2020","December 2020","December 2020","April 15, 2020",,"May 27, 2020","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04346693"
49,"NCT04335123","Study of Open Label Losartan in COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Losartan","Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg","University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00145514","March 25, 2020","September 2020","October 2020","April 6, 2020",,"April 24, 2020","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04335123"
50,"NCT04394182","Ultra Low Doses of Therapy With Radiation Applicated to COVID-19","ULTRA-COVID","Recruiting","No Results Available","Pneumonia, Viral|Cytokine Storm","Radiation: Ultra-Low-dose radiotherapy|Device: ventilatory support with oxygen therapy|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Piperacillin/tazobactam|Drug: Low molecular weight heparin|Drug: Corticosteroid injection|Drug: Tocilizumab","Oxygen Therapy Status at Day 2|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2|Blood Gas Analysis at Day 2|Blood Test at Day 2|Oxygen Therapy Status at Day 5|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 5|Blood Test at Day 5|Oxygen Therapy Status at Day 7|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 7|Blood Test at Day 7|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan at Day 7|Recovery time|COVID-19 status|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan al Month 1|Acute Toxicity","Fundacion GenesisCare|Hospital La Milagrosa|Hospital Vithas Valencia Consuelo","All","18 Years to 120 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20.4.1597-GHM","April 21, 2020","December 31, 2020","April 21, 2021","May 19, 2020",,"May 19, 2020","Hospital La Milagrosa, GenesisCare, Madrid, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04394182"
51,"NCT04366245","Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection",,"Recruiting","No Results Available","SARS-CoV 2","Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection","Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).|Efficacy: Death from any cause|Efficacy: Need for mechanical ventilation|Efficacy: Any of the following analytical data after 72h of randomization.|Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.|Efficacy. Mortality on days 14 and 28.|Efficacy: Proportion of patients who required mechanical ventilation|Efficacy: Proportion of patients who develop analytical alterations.|Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.|Efficacy: PCR negative for SARS-CoV-2|Efficacy: Proportion of patients who required treatment with Tocilizumab|Efficacy: Duration of hospitalization (days)|Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample|Virology and immunological variables: Total antibody quantification|Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.","Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PC/COVID-19","April 23, 2020","December 2021","December 2021","April 28, 2020",,"June 5, 2020","Hospital U. Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital U. Puerto Real, Puerto Real, Cádiz, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Hospital U. Torrecárdenas, Almería, Spain|Hospital U. Puerta del Mar, Cádiz, Spain|Hospital U. Virgen de las Nieves, Granada, Spain|Hospital U. San Cecilio, Granada, Spain|Hospital Juan Ramón Jiménez, Huelva, Spain|Hospital Regional U. de Málaga, Málaga, Spain|Hospital U. Virgen de la Victoria, Málaga, Spain|Hospital Unversitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital U. Nuestra Señora de Valme, Sevilla, Spain|Hospital San Juan de Dios, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT04366245"
52,"NCT04392414","Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease",,"Recruiting","No Results Available","COVID-19","Biological: COVID-19 convalescent hyperimmune plasma|Biological: Non-convalescent fresh frozen plasma (Standard plasma)","The number and proportion of patients with the normal body temperature (≤37.2 C) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy|Days before mechanical ventilation|Days of need for oxygen therapy|Days of stay in the ICU|Days of hospitalization|Changes of the titer of the SARS-CoV-2 antibodies in the blood plasma of patients|Dynamics of the cytokine profile|Incidence of the cytokine storm development and the need of administering cytokine storm inhibitors|Dynamics of the level of C-reactive protein|30-day mortality rate","Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CovPlas-Covid19","May 1, 2020","August 1, 2020","September 15, 2020","May 18, 2020",,"June 4, 2020","Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04392414"
53,"NCT04414631","Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19",,"Not yet recruiting","No Results Available","Coronavirus Infections","Drug: Conestat alfa","Disease severity|Time to clinical improvement|Proportion of participants alive and not having required invasive or non-invasive ventilation|Proportion of subjects with an ALI (defined by PaO2/FiO2 ratio of <300mmHg)","University Hospital, Basel, Switzerland|Pharming Technologies B.V.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-01252; me20Osthoff3","June 2020","June 2021","July 2021","June 4, 2020",,"June 4, 2020","University Hospital Basel, Division of Internal Medicine, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT04414631"
54,"NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","POPS or POP02","Recruiting","No Results Available","Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:","Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling","Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 20 Years   (Child, Adult)",,"5000","Other|Industry|NIH","Observational","Observational Model: Other|Time Perspective: Prospective","Pro00103838","March 5, 2020","April 24, 2024","April 24, 2024","February 20, 2020",,"May 14, 2020","Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|Colorado University Denver, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Childrens Mercy Hospital, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, United States|Kravis Children's Hospital at Mt. Sinai, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|University Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04278404"
